Emerging diagnostics PhAST focuses on rapid diagnostic imaging to accelerate pathogen detection and antibiotic susceptibility testing, presenting a sales angle with hospitals and labs seeking faster turnaround times and improved antimicrobial stewardship.

Single-cell imaging Leverage PhAST's unique single-cell imaging platform as a differentiator to target research institutions and biotech firms exploring novel microbiology assays and rapid phenotypic testing capabilities.

Small team agility With 11-50 employees, PhAST is likely agile and open to strategic partnerships, pilot programs, and co-development opportunities that can accelerate go-to-market and reduce sales cycle friction.

Funding and growth signals Current revenue range and recent funding indicate a growth-stage company; potential upsell opportunities include expanded assay panels, software analytics, and integration with existing lab information systems.

Adjacent markets Similar-company landscape and the biotechnology milieu suggest targeting academic labs, contract research organizations, and early-stage biotechs in infectious disease and antimicrobial testing for collaboration or licensing deals.